// App-Quantinova.ai

6016 : A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.

Researchers

Presenter

  • Matthew H. Taylor

Principal Investigators

  • Drew W. Rasco

  • Marcia S. Brose

  • Nicholas J. Vogelzang

  • Stephen Lane Richey

  • Allen Lee Cohn

  • Donald A. Richards

  • Daniel E. Stepan

  • Corina E. Dutcus

  • Matthew Guo

  • Robert Charles Shumaker

  • Emmett V. Schmidt

  • Lori J. Wirth

Medical Centers

  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • START-South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX

  • Department of Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Texas Oncology, The US Oncology Network, McKesson Specialty Health, Fort Worth, TX

  • Rocky Mountain Cancer Center, US Oncology, Denver, CO

  • US Oncology Research, Tyler, TX

  • Eisai Inc, Woodcliff Lake, NJ

  • Merck & Co., Inc., Kenilworth, NJ

  • Massachusetts General Hospital Cancer Center, Boston, MA

Locations

  • United States

Companies

  • Eisai Inc.

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Cancer antigen 15-3

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Lenvatinib

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • II

Study Id's

  • NCT02501096

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved